Roche’s James Sabry zeroes in on a new pathway for protein degradation — and he’s paying $135M cash for a hot ticket
We don’t know all the details about what exactly is driving Roche BD chief James Sabry this time, but he’s clearly on a preclinical tear.
Six weeks after paying out $190 million cash to partner with Arrakis on a transformative collaboration on their preclinical effort to drug RNA, the pharma giant dealmaker is back with $135 million in cash to collaborate with Vividion, which clearly won over Roche to a new way to achieve protein degradation — one of the hottest tickets in R&D that has emerged in recent years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.